Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection

Infect Control Hosp Epidemiol. 2023 Feb;44(2):302-304. doi: 10.1017/ice.2021.466. Epub 2022 Feb 11.

Abstract

We evaluated the interference of the mucosal barrier injury (MBI) laboratory-confirmed bloodstream infection (MBI-LCBI) criteria on the central-line-associated bloodstream infection (CLABSI) incidence density, and the proportion of catheter-related bloodstream infections (CRBSIs) among those classified as MBI. We detected 339 CLABSIs: 15.0% were classified as MBI-LCBIs, and among these, 19.6% were classified as CRBSIs.

MeSH terms

  • Catheter-Related Infections* / diagnosis
  • Catheter-Related Infections* / epidemiology
  • Catheterization, Central Venous* / adverse effects
  • Central Venous Catheters*
  • Communicable Diseases*
  • Hematologic Neoplasms* / complications
  • Humans
  • Neoplasms*
  • Retrospective Studies
  • Sepsis* / epidemiology